Similarly, icaritin modulates metastasis-related proteins (e.g., MMP-9, E‐cadherin, N‐cadherin, and Vimentin) and exhibits inhibitory effects in multiple myeloma (RPMI 8226 and OPM-2), ovarian cancer (A2780), esophageal cancer stem cells (ECA109) and endometrial cancer (RL95-2 and Ishikawa) cells [732, 747–749]. This evidence concerns the gene MMP9 and ovarian carcinoma.